Alx Oncology Holdings (ALXO) Preferred Stock Liabilities (2019 - 2020)
Alx Oncology Holdings recorded quarterly Preferred Stock Liabilities of $175.0 million in Q2 2020, little changed quarter-over-quarter from $175.0 million in Q1 2020, and up 148.77% year-over-year from $70.4 million in Q3 2019.
Alx Oncology Holdings' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $175.0 million for Q2 2020.
- In Q2 2020, Preferred Stock Liabilities rose 148.77% year-over-year to $175.0 million; the TTM figure through Jun 2020 stood at $175.0 million (up 148.77% YoY), while the FY2019 annual figure was $70.4 million, up 15.48% from the prior year.
- Preferred Stock Liabilities came in at $175.0 million for Q2 2020 at Alx Oncology Holdings, roughly flat from $175.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $175.0 million in Q1 2020 to a low of $70.4 million in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 175.04 Mn |
| Mar 31, 2020 | 175.04 Mn |
| Dec 31, 2019 | 70.36 Mn |
| Sep 30, 2019 | 70.36 Mn |
| Jun 30, 2019 | 70.36 Mn |